MissionIR Articles
-
MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Conditional FDA Acceptance of Proprietary Name for Lead Drug Candidate
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has received conditional FDA acceptance of the proprietary name REQORSA(TM), its lead drug candidate for treatment of…
-
MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Appoints Eric Chapdelaine to Senior Manufacturing Team
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for cancer and diabetes patients, today announced the promotion of Eric Chapdelaine to vice president of manufacturing. According to the update, Chapdelaine’s promotion…
-
MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) CEO Scheduled to Present at LD Micro Event
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, is slated to present at an upcoming LD Micro virtual event. GNPX’s Zoom presentation is scheduled for…
-
MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Appoints Seasoned Biotech Executive to Advance Expanding IP Estate
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced it has named Thomas C. Gallagher, Esq. as its senior vice president of Intellectual Property…
-
MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Appoints New VP to Oversee Regulatory Affairs
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has appointed William E. Gannon Jr., MD, MBA, as vice president of Regulatory Affairs. With more than…
-
MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Invited to Present at Prestigious LD 500 Virtual Investor Conference
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has announced that it joins the lineup of presenters at this year’s LD 500 Virtual Investor Conference. The…
-
MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) CEO Again Featured on ‘Big Biz Show,’ to Present at Proactive’s One2One Virtual Investor Forum
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, on Thursday announced participation by its chairman and CEO, Rodney Varner, in a second-round live interview on…
-
MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces $2.59M NIH Research Grant to Lead Researcher Behind Its Diabetes Gene Therapy
Genprex (NASDAQ: GNPX), today announced that Dr. George K. Gittes, MD of the University of Pittsburgh, the lead researcher that developed the company’s potentially curative diabetes gene therapy, was awarded a grant of $2.59 million…
-
MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Joins Russell 3000(R) Index
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that it was added to the Russell 3000(R) Index after the market closed on Friday,…
-
MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Another Step in Advancement of Lead Drug Candidate for NSCLC
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that the United States Adopted Names (“USAN”) Council has approved the non-proprietary name quaratusugene ozeplasmid…
-
MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) and Aldevron Expand Manufacturing Program to Advance Oncoprex(TM)
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced its entry into a new agreement with manufacturing partner Aldevron, LLC for expansion of Genprex’s…
-
MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Selected to Join Russell 3000(R) Index
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that it is scheduled to join the U.S. broad-market Russell 3000 Index, which includes the…
-
MissionIRNewsBreaks – Genprex, Inc.’s (NASDAQ: GNPX) Chairman and CEO to Present at the MoneyShow June Virtual Event
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that it will present at the MoneyShow June Virtual Event at 12:50 p.m. EDT on…
-
MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Secures $2.5 Million in Cash Proceeds from Recent Warrant Exercises
Genprex (NASDAQ: GNPX) today announced the exercise of warrants to purchase approximately 5.4 million shares of common stock issued in connection with capital raises in May 2018 and November 2019 with two institutional investors at…
-
MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Expands Oncology Franchise via Exclusive Worldwide Patent and Technology License Agreement
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that it has entered into a patent and technology license agreement with The University of…
-
MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Issues Shareholder Letter Highlighting Oncoprex(TM) Progress, License Agreement for a Diabetes Drug Candidate and Other Achievements
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced its issuance of an April 2020 Shareholder Letter. According to the update, the letter highlights…
-
MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Appoints Accomplished Executive Shannon Inman to Drive Launch of Key Clinical Trials
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced the appointment of Shannon Inman as Vice President of Global Clinical Operations. According to the…
-
MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Strategic Board Appointments of Three Biotechnology and Healthcare Industry Leaders
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced the appointment of three new members to its Board of Directors. The new appointments, which…
-
MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Expands Leadership Team with Appointment of Accomplished Life Science Executives
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced the appointment of Catherine M. Vaczy as executive vice president and chief strategy officer and…
-
MissionIRNewsBreaks – Genprex, Inc.’s (NASDAQ: GNPX) Lead Researcher Behind its Diabetes Gene Therapy Featured in New Video Interview
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing treatments for cancer and other serious diseases, today announced that Dr. George Gittes, the lead researcher and Harvard graduate that developed Genprex’s new potentially…
Search Articles
Latest Articles
- MissionIRNewsBreaks – Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Marks Pivotal Moment on Path to 2026 Rare Earth Oxide Production
- PowerBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: 103) Marks Bold Entry Into the Growing Battery Storage Market with 4.99 MW BESS in Ontario
- Soligenix Inc. (NASDAQ: SNGX) Working to Advance Heat-Stable Ricin Vaccine with Promising Efficacy
- New Pacific Metals Corp. (NYSE American: NEWP) (TSX: NUAG) Eyes Bolivia’s Untapped Silver Potential Amid Global Supply Gaps
- MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q2 2025 Results, Advances TPI 287 Toward Phase 2 GBM Trial